Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics that enable clinicians to detect scientifically validated biomarkers and optimally treat GI diseases, including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS.
Gemelli Biotech was established in 2018 by healthcare practitioners with expertise in patient care focused on the gastrointestinal system and is headquartered in Raleigh, North Carolina.
Gemelli Biotech is partnered with the Medically Associated Science and Technology (MAST) program at Cedars Sinai (Los Angeles) to be a laboratory that is patient-focused and able to meet the needs for precision diagnostics for personalized management of gastrointestinal functioning.
Gemelli Biotech offers two diagnostic tests that provide information on the microbes residing within the gastrointestinal system: the IBS-smart test, which is a blood test assessing for particular antibody levels indicative of IBS; and the trio-smart test, which is a breath test to assess levels of hydrogen, methane, and hydrogen sulfide for abnormalities. The results from these tests can facilitate diagnosing and managing specific gastrointestinal issues such as irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), intestinal methanogenic overgrowth (IMO), and excess hydrogen sulfide.
Their vision aims to be “a lab that operates mindfully, treats patients compassionately, and empowers clinicians to find answers in more efficient and effective ways.”
Gemelli Biotech has support and advisement from healthcare professionals with clinical and research focus on various areas of gastroenterology and hepatology, including motility, function, and bowel and intestinal disorders.
Gemelli Biotech’s partnership with the MAST program at Cedars-Sinai enables them to participate in the continued advancement of microbiome diagnostic testing, incorporating new, innovative biotechnology in patient testing and care management.
Gemelli Biotech leverages leading biological discoveries related to the microbiome to provide non-invasive precision diagnostics which enable clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS.
